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Cervical cancer is the second most common cancer after breast cancer in 
South African (SA) women.[1] Persistent human papilloma virus (HPV) 
infection is linked to both cervical cancer and genital warts.[2] High-risk 
genotypes HPV 16 and 18 are associated with 70% of cervical cancers, 
and HPV 6 and 11 with 90% of genital warts.[2]
Vaccination against HPV infection offers protection against the 
development of cervical cancer, especially if administered before the 
onset of sexual activity.[2] Two vaccines are available in SA: Cervarix 
(bivalent vaccine with activity against HPV 16 and 18) and Gardasil 
(quadrivalent vaccine against HPV 6, 11, 16 and 18).[2]
High-income countries such as the USA have introduced HPV 
vaccination for both males and females.[3] However, the World Health 
Organization (WHO) recommends that in resource-constrained 
settings it is more cost-effective to vaccinate only females.[2]
Demonstration of the non-inferiority of the two-dose v. the three-
dose regimens[3,4] probably provided the basis for the SA government 
to nationally roll out HPV vaccination (two doses of Cervarix given 6 
months apart) to all female Grade 4 learners at government schools, 
targeting approximately 500 000 learners.[5]
According to the United Nations Population Fund, a key 
consideration in the integration of HPV vaccine delivery into health 
systems is budgeting for vaccines and service delivery costs.[6]
Objective
Modelling for this costing study was based on the HPV vaccination 
demonstration project.[7] The objective was to use the costs 
determined for the demonstration project as the basis for estimating 
the costs of vaccinating all Grade 4 (9 - 10-year-old) learners in 
KwaZulu-Natal Province (KZN) (female compared with both male 
and female learners) using either the two- or three-dose regimens for 
both Cervarix and Gardasil.
Methods
This was a retrospective cost analysis using data collected during 
the HPV vaccination demonstration project conducted in KZN in 
2011.[7]
Data collection and analysis
Costs of the HPV vaccination demonstration project[7]
Financial and economic costs were estimated using adapted versions 
of established costing guidelines.[8] Actual expenditures (2014 costs) 
were determined for personnel, goods and services. Economic costs 
included donated vaccines.
Cost data were distributed into four categories: personnel costs based 
on government salary scales for 2014; recurrent costs for procurement 
of vaccines and waste management; transport costs (based on the 
Automobile Association of South Africa rates); and capital costs for 
cold boxes and additional refrigerators. Capital costs for equipment 
already available at the hospital pharmacy were not included.
Costs of training and community mobilisation and information, 
education and communication were included for the demonstration 
project and then treated as start-up costs and annualised over 5 years. 
Building costs and overheads (e.g. maintenance, water and electricity) 
were not included.
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Results. The 2014 current cost of delivering three doses of Gardasil was ZAR510 per learner. The projected cost of delivering Cervarix to female 
learners at two or three doses over the period 2014 - 2018, adjusted for inflation, was ZAR172 717 342 and ZAR250 048 426, respectively. 
Similarly, the cost for Gardasil at these doses was ZAR197 482 200 and ZAR287 194 361, respectively. For male and female learners the cost for 
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doses of Gardasil ranged from ZAR193 104 566 to ZAR201 859 798. For three doses the cost ranged from ZAR280 828 057 to ZAR293 560 614.
Conclusion. This study gives decision makers a basis for structured planning and cost apportionment to ensure effective roll-out of the 
HPV vaccination programme.
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Costs assumed a price per dose of USD8 and 
USD10 for the bivalent and quadrivalent 
vaccines, respectively.[9]
All cost data were adjusted to the year 
2014 using country-specific gross domestic 
product (GDP) inflators[10] and were converted 
to US dollars using average 2014 exchange 
rates of 11 ZAR = 1 USD. Using an ingredients 
approach, the financial and economic costs 
were determined per fully immunised female 
learner.
Estimated costs of vaccinating all  
female learners (Grade 4, age 9 and 10 
years) in KZN 
The model estimated the costs of a school-
based delivery programme targeting female 
learners in Grade 4 (age 9 and 10 years). 
The model was constructed to estimate the 
incremental economic costs of a scaled-up 
vaccination programme in KZN, reflecting 
the plans of the SA government.[5]
The model involved two steps: quantities of 
resources were estimated on the processes 
used during the school-based vaccination 
project,[7] for input into the WHO planning 
and costing tool for estimating the costs of 
introducing HPV vaccines.[8] Unit costs or 
prices were assigned to the necessary inputs. 
The model calculated total costs for KZN 
and the cost per fully immunised learner.
Costs were estimated for a ‘base-case 
scenario’ using a number of ‘base-case’ 
assumptions (Table 1). Low-cost assump-
tions assumed only two vaccinations, and 
excluded HPV vaccine costs. High-cost 
assumptions assumed three doses of the 
vaccine and included vaccine costs.
Sensitivity analyses were carried out using 
estimates of the consumer price index (CPI) 
and population variations to generate the 
largest possible range of costs in an analysis 
of extremes. Fig. 1 shows the observed 
and projected population of female and 
male learners in KZN[11] eligible for HPV 
vaccination. Using data for 2002 - 2013, 
various non-linear regression curves were 
fitted to the data and assessed as to which 
fitted the data best for the observed period. 
This best-fit non-linear curve and associated 
95% confidence intervals (CIs) (uncertainty) 
were used to project population totals by 
gender and year for the period 2014 - 2018. 
This projection was then multiplied by the 
projected costs and also took into account 
inflation to estimate variations in costs of HPV 
vaccine provision. The estimated average CPI 
increase was obtained from Statistics South 
Africa to calculate the nominal increase in 
prices for the period 2014 - 2018.[12]
All analyses were conducted using Stata 
13.0 SE (Stata Statistical Software: Release 
13, StataCorp LP, USA). Non-linear 
regression analyses were conducted using 
the ‘nl’ programme in Stata.[13]
Ethical considerations
Ethical approval for the demonstration 
project was obtained from the Institutional 
Ethics Committee at the University of Cape 
Town (HREC REF:012/2011). Approval to 
conduct the project in the two districts 
was obtained from the KZN provincial 
departments of health and education.
Results
Total cost of the HPV demonstration 
project
The economic cost per learner (Table 2) of deliv-
ering three doses of Gardasil HPV vaccine was 
ZAR510.28 (USD46.39). Administration, super-
vision, social mobilisation and training account-
ed for 35.3% of total project costs. Procure-
ment accounted for 64.7% or ZAR211 860 
(USD19 260) of total costs. Based on the cost 
per learner, the total economic project costs of 
delivering three doses of HPV vaccine to 963 
female learners in the Zululand District were 
estimated to be ZAR491 400 (USD44 673).
Table 1. Input parameters for modelling of a scaled-up vaccination programme for KZN
Base case Low cost High cost
Vaccinations, n 3 2 3
Additional vaccination trips, n 3 2 4
Total km for school visited 1 550 1 550 1 550
Eligible schools, % 80 75 100
Wastage rate (vaccines), % 1 0.5 2
Vaccination coverage, %
Rate for first dose 99.69
Rate for second dose 97.92
Rate for third dose 97.82
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Fig. 1. Observed and projected populations of female and male learners in KZN eligible for HPV 
vaccination.
Table 2. Total economic costs for  
the HPV demonstration project  
(three doses)
Cost, ZAR
School health teams 118.25
Pharmacy 8.17
Consumables 5.26
Fridge 8.31
Printing 2.92
Transport 37.37
Gardasil 330.00
Cost/learner 510.28
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Costs of a KZN provincial vaccination programme
Projected costs over a 5-year period of providing HPV vaccines to 
female learners only or to both male and female learners
The costs of providing a two- or three-dose vaccine (Cervarix or 
Gardasil) to all eligible learners in KZN were determined.
Table 3 shows the estimated incremental economic costs of a scaled-
up vaccination programme delivering two and three doses of HPV 
vaccine (Cervarix or Gardasil) to female learners alone. The costs 
of delivering two and three doses to both female and male learners 
are set out in Table 4 (Cervarix) and Table 5 (Gardasil). The costs of 
procurement, including vaccines and supplies, shipment of vaccines 
to regional level, transport to districts and distribution to health 
facilities, account for the largest share of financial and economic costs 
(35.3% and 64.7%, respectively). The costs of vaccination include the 
cost of nurses’ and teachers’ time and administration.
Over the period 2014 - 2018, the projected cost of providing Cervarix 
at two doses to female learners only, adjusted for inflation (Table 3), 
ranged from ZAR34 397 341 (USD3 127 031) to ZAR34  689  596 
(USD3 153 600), with a total overall cost of ZAR172 717 342 
(USD15 701 577) over the 5-year period. For Cervarix at three 
doses, the cost ranged from ZAR49 798 132 (USD4 527 103) to 
ZAR50 221 238 (USD4 565 567), with a total overall cost for the 
5-year period of ZAR250 048 426 (USD22 731 675). The percentage 
incremental cost of providing a three-dose regimen was in the order 
of 44.8% over the 5-year period.
Similarly, the projected cost for providing Gardasil at two 
doses to female learners only over the same period, adjusted for 
inflation (Table 3), ranged from ZAR39 329 361 (USD3 575 396) 
to ZAR39 663 519 (USD3 605 774), with a total overall cost of 
ZAR197 482 200 (USD17 952 927). For Gardasil at three doses, the 
cost ranged from ZAR57 195 892 (USD5 199 627) to ZAR57 681 852 
(USD5  243  805), with a total overall cost for the 5-year period of 
ZAR287 194 361 (USD26 108 578). The percentage incremental cost 
of providing a three-dose regimen was in the order of 45.7% over the 
5-year period. The incremental cost of providing the two- or three-
dose regimen of Gardasil over the 5-year period was ZAR24 764 857 
(USD2 251 351) and ZAR37 145 935 (USD3 376 903), respectively.
The projected cost of providing Cervarix at two doses to both male 
and female learners for the period 2014 - 2018 (Table 4) ranged from 
ZAR67 858 042 (USD6 168 913) to ZAR82 345 798 (USD7 485 982), 
and for Cervarix at three doses from ZAR98 240 260 (USD8 930 933) 
to ZAR119 214 648 (USD10 837 695). The total overall cost for the 
5-year period for Cervarix at two or three doses was ZAR373 101 312 
(USD30 696 679) and ZAR540 150 713 (USD4  9137 012), respec-
tively.
Similarly, for Gardasil at two doses to male and female learners 
(Table 5), the projected cost over the 5-year period ranged 
from ZAR77 587 782 (USD10 837 695) to ZAR94 152 846 
(USD8 559 350), and for Gardasil at three doses from ZAR112 834 338 
(USD10  257  667) to ZAR136 924 576 (USD12 447 689). The total 
Table 3. Projected baseline costs (ZAR) over a 5-year period for 
providing HPV vaccines (Cervarix or Gardasil at either two or 
three doses) to female learners only
Cervarix Gardasil
Year 2 doses 3 doses 2 doses 3 doses
2014 34 397 341 49 798 132 39 329 361 57 195 892
2015 34 470 405 49 903 909 39 412 900 57 317 382
2016 34 543 468 50 009 685 39 496 440 57 438 872
2017 34 616 532 50 115 462 39 579 980 57 560 362
2018 34 689 596 50 221 238 39 663 519 57 681 852
Total 172 717 342 250 048 426 197 482 200 287 194 361
Table 4. Projected baseline costs (ZAR) over a 5-year period for providing HPV vaccine (Cervarix at either two or three doses)  
to female and male learners
2 doses 3 doses
Year Mean Lower 95% CI Upper 95% CI Mean Lower 95% CI Upper 95% CI
2014 67 858 042 67 338 034 68 378 081 98 240 260 97 487 427 98 993 137
2015 70 854 600 69 625 058 72 084 141 102 578 472 100 798 426 104 358 518
2016 74 144 035 71 681 793 76 606 278 107 340 693 103 776 026 110 905 361
2017 77 898 837 73 467 423 82 330 251 112 776 640 106 361 140 119 192 140
2018 82 345 798 74 938 302 89 753 257 119 214 648 108 490 579 129 938 663
Total 373 101 312 357 050 610 389 152 007 540 150 713 516 913 598 563 387 819
Table 5. Projected baseline costs (ZAR) over a 5-year period for providing HPV vaccine (Gardasil at either two or three doses) 
to female and male learners
  2 doses 3 doses
Year Mean Lower 95% CI Upper 95% CI Mean Lower 95% CI Upper 95% CI
2014 77 587 782 76 993 213 78 182 385 112 834 338 111 969 669 113 699 059
2015 81 013 997 79 608 159 82 419 834 117 817 013 115 772 533 119 861 494
2016 84 775 084 81 959 796 87 590 372 123 286 686 119 192 470 127 380 903
2017 89 068 263 84 001 456 94 135 070 129 530 170 122 161 615 136 898 725
2018 94 152 846 85 683 236 102 622 414 136 924 576 124 607 394 149 241 696
Total 426 597 971 408 245 859 444 950 075 620 392 784 593 703 680 647 081 877
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overall cost for the 5-year period for Gardasil at two or three 
doses was ZAR426 597 971 (USD38 781 634 and ZAR620 392 784 
(USD56 399 344), respectively.
The incremental cost of extending the vaccination to male 
learners for the two- and three-dose regimens of Cervarix was 
ZAR200 383 970 (USD18 217 082) and ZAR290 102 288 
(USD26  372  935), respectively, and that for the two- and three-
dose regimens of Gardasil ZAR229 115 771 (USD20 829 115) and 
ZAR333 198 423 (USD30 290 766), respec tively. 
Projected annual costs over a 5-year period for fully immunised 
female learners, taking into account population variation 
estimates
Sensitivity analysis used the baseline costs for 2014 and 95% CIs that 
take into account variations in the population estimates as shown in 
Fig. 1. The assumption is that full coverage based on economic costs, 
i.e. funding for the vaccines, will be provided by KZN Department 
of Health. The distribution of costs across programme elements 
was based on the HPV vaccination demonstration project shown 
in Table 2.
The projected costs based on the baseline cost of providing 
HPV vaccines to female learners (Table 3) adjusted for population 
variations (with 95% CIs) were determined for both Cervarix 
and Gardasil (two- and three-dose regimens) for each of the 
years from 2014 to 2015 (Table 6). The overall projected cost of 
delivering Cervarix at two and three doses to female learners for 
the period 2014 - 2018 was ZAR172 717 342 (USD15 701 577) and 
ZAR250  048 426 (USD22  731) respectively (Table 6). Taking into 
account population variation over the same period, the cost of a 
two-dose regimen ranged from ZAR168 888 677 (USD15 353 516) 
to ZAR176 545 977 (USD16 049 634) at the lower and upper 95% 
CIs, respectively. In contrast, for the three-dose regimen the cost 
ranged from ZAR244 505 544 (USD22 227 777) to ZAR255 591 263 
(USD23 235 569) at the lower and upper 95% CIs, respectively.
Similarly, the overall projected cost of delivering Gardasil at 
two and three doses to female learners was ZAR197 482 200 
(USD17 952 927) and ZAR287 194 361 (USD26 108 578), respectively 
(Table 6). Taking into account population variation over the 5-year 
period, the cost of a two-dose regimen ranged from ZAR193 104 566 
(USD17 554 961) to ZAR201 859 798 (USD18 350 891) at the lower 
and upper 95% CIs, respectively. In contrast, for the three-dose 
regimen the cost ranged from ZAR280 828 057 (USD25 529 823) to 
ZAR293 560 614 (USD26 687 329) at the lower and upper 95% CIs, 
respectively.
Regardless of whether Cervarix or Gardasil is provided and 
irrespective of the dosage regimen, the population projections 
suggest a negative growth at the lower limit of the CI over the 5-year 
period, resulting in a decrease in costs. At the upper limit of the CI 
the projections show a small increase in population growth, resulting 
in a marginal increase in costs.
Discussion
This costing study based on the HPV vaccination demonstration 
project]7] provides the basis for estimating the costs of including 
both female and male learners in the provincial HPV vaccination 
programme. Limited to the province of KZN, it did not take into 
account variations between districts, for example in terms of resources 
(availability and distribution of school health teams, transport, 
logistics, and cold-chain management) and urban populations. 
However, it provides the cost input parameters to monitor the 
implementation of the vaccination programme
While it is noted that the implementation of new health 
interventions in low- to middle-income countries may take time 
to achieve the anticipated public health outcomes, a cost-benefit 
analysis based on the number of cases of cervical cancers and HPV-
related warts averted should be undertaken to determine future 
downstream cost savings through the introduction of the HPV 
vaccination programme in SA.
A Tanzanian study that conducted a top-down analysis of the costs 
of delivering three doses of HPV vaccine to 4 211 girls estimated the 
total economic costs to be USD349 000 (which included a vaccine price 
of USD5 per dose).[14] This cost per fully immunised learner (USD78) 
is almost two-fold greater than reported in our study. However, 
when scaled up the Tanzanian costs are almost 50% lower (USD46.5 
v. USD26.4). Incremental economic scaled-up costs for school-
based vaccination of 50 290 girls were estimated at USD1.3 million. 
Economic scaled-up costs per fully immunised girl were USD26.41 
per dose. Excluding vaccine costs, the vaccine could be administered 
at an incremental economic cost of USD3.09 per dose and USD9.76 
per fully immunised girl. Financial scaled-up costs, excluding costs of 
the vaccine and salaries of existing staff, were estimated at USD1.73 
per dose.[14]
A cross-country study conducted in Peru, Uganda and Vietnam 
estimated the economic delivery cost per vaccine as USD3.88 in 
Table 6. Baseline and 95% CI HPV vaccine (Cervarix and Gardasil) administration costs (ZAR) for female learners
Cervarix: Female learners Gardasil: Female learners
Year 2 doses, mean (95% CI) 3 doses, mean (95% CI) 2 doses, mean (95% CI) 3 doses, mean (95% CI)
2014 34 397 341
(34 253 568 - 34 541 084)
49 798 132
(49 589 987 - 50 006 233)
39 329 361
(39 164 973 - 39 493 714)
57 195 892
(56 956 826 - 57 434 907)
2015 34 470 405
(34 146 647 - 34 794 163)
49 903 909
(49 435 193 - 50 372 624)
39 412 900
(39 042 720 - 39 783 080)
57 317 382
(56 779 037 - 57 855 728)
2016 34 543 468
(33 925 965 - 35 160 972)
50 009 685
(49 115 705 - 50 903 665)
39 496 440
(38 790 396 - 40 202 484)
57 438 872
(56 412 087 - 58 465 658)
2017 34 616 532
(33 558 072 - 35 674 992)
50 115 462
(48 583 095 - 51 647 828)
39 579 980
(38 369 753 - 40 790 205)
57 560 362
(55 800 355 - 59 320 369)
2018 34 689 596
(33 004 425 - 36 374 766)
50 221 238
(47 781 563 - 52 660 913)
39 663 519
(37 736 723 - 41 590 315)
57 681 852
(54 879 752 - 60 483 953)
Total
 
172 717 342
(168 888 677 - 176 545 977)
250 048 426
(244 505 544 - 255 591 261)
197 482 200
(193 104 566 - 201 859 798)
287 194 361
(280 828 057 - 293 560 614)
RESEARCH
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Peru, USD3.15 (school based) and USD1.44 (integrated outreach) 
in Uganda, and USD2.08 (school based) and USD1.92 (integrated 
outreach) in Vietnam.[15] The Tanzanian and other studies show that 
the lower economic costs per fully immunised learner are achieved 
not only through lower vaccine costs, but mainly through lower 
delivery costs.[14-15]
The cost-effectiveness of including boys in HPV vaccination 
programmes is dependent on vaccine pricing, HPV prevalence, and 
uptake of cancer screening and treatment.[16]
A cost utility study conducted in New Zealand[17] found that it was 
not cost-effective to vaccinate boys in addition to girls. Significantly, 
for vaccination of boys to be cost-effective, the cost of the vaccine 
needs to be very low and administration costs minimal.[17] Similarly, 
in Brazil it was found that it was not cost-effective to include boys.[18]
Conclusion
This study provides decision makers with a framework for allocating 
resources to determine financial and economic costs for structured 
planning to effectively roll out the HPV vaccination programme 
nationally. Costing studies can inform budget impact analyses and 
cost minimisation studies to decide on optimal delivery strategy.
A two-dose regimen of either Cervarix or Gardasil is less costly 
than three doses, with reported equivalent benefits. In low- to 
middle-income countries vaccination of female learners is more cost-
effective than vaccination of both males and females.
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